Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Eledon Pharmaceuticals, Inc.

CIK 1404281 ELDN·Pharmaceutical Preparations · All EDGAR filings ↗

Material weakness Filing comparison

Eledon Pharmaceuticals, Inc. reported internal control effective again after a material weakness

Material weakness in internal control Internal control reported effective

The weakness was first reported on 2025-08-14 — 272 days and 3 annual reports before this one.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. Although the Company concluded that as of December 31, 2025 its internal control over financial reporting was effective, the Company cannot provide assurances that the remediated material weakness will not reoccur, or that…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-11-14
Prior form
10-Q
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
Yes
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
3
Weakness days reported
272
Weakness first reported
2025-08-14
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.